Press Release
CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com
CORCEPT THERAPEUTICS TO PRESENT AT THOMAS WEISEL PARTNERS GROWTH FORUM ON JUNE 13, 2005
MENLO PARK, Calif.
(June 8, 2005) -- Corcept Therapeutics Incorporated (Nasdaq: CORT)
today announced that the company will present at the Thomas Weisel Partners
Growth Forum on June 13th at 3:15 p.m. (PDT) at the Four Seasons Hotel
in San Francisco. The presentation will cover the company's clinical and
corporate progress.
A live and subsequent archive of the Corcept presentation will be available
on June 13, 2005 via webcast at: http://www.veracast.com/webcasts/twp/GF2005/99112507.cfm.
The webcast will be available for 2 weeks.
About Corcept Therapeutics
Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged
in the development of drugs for the treatment of severe psychiatric and
neurological diseases. Corcept's lead product, CORLUX®, is currently
in Phase III clinical trials for the treatment of the psychotic features
of psychotic major depression (PMD). The drug is administered orally to
PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist,
appears to mitigate the effects of the elevated and abnormal release patterns
of cortisol seen in PMD. Corcept is also conducting a clinical trial to
evaluate the safety and efficacy of our product in improving cognition
in patients with mild to moderate Alzheimer's disease. For additional
information about the company, please visit www.corcept.com.